Outcome of myeloma patients with COVID5 19 on active lenalidomide-based therapy: 6 Does lenalidomide protect from severe 7 COVID-19?

Patients with haematological cancers and concurrent coronavirus disease 2019 (COVID-19) reportedly have poor outcomes as indicated by high hospitalisation rates, high case fatality rates in mechanically ventilated patients, and a high mortality rate of ≥10% [1], [2], [3]. A recent small study report...

Full description

Autores:
Tipo de recurso:
Article of investigation
Fecha de publicación:
2020
Institución:
Universidad de Bogotá Jorge Tadeo Lozano
Repositorio:
Expeditio: repositorio UTadeo
Idioma:
eng
OAI Identifier:
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13586
Acceso en línea:
https://doi.org/10.1016/j.hemonc.2020.08.002
http://hdl.handle.net/20.500.12010/13586
Palabra clave:
COVID5 19
Myeloma patients
Lenalidomide-based therapy
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Rights
License
Abierto (Texto Completo)
Description
Summary:Patients with haematological cancers and concurrent coronavirus disease 2019 (COVID-19) reportedly have poor outcomes as indicated by high hospitalisation rates, high case fatality rates in mechanically ventilated patients, and a high mortality rate of ≥10% [1], [2], [3]. A recent small study reported a high mortality rate among patients with myeloma and concurrent COVID-19 infection [4]. Interestingly, one large study reported that active or recent chemotherapy was not a predictor of severe disease, whereas checkpoint inhibitor therapy and age over 65 years were associated with adverse outcomes [1]. Here we describe the outcomes of three consecutive patients with myeloma and concurrent COVID-19 infection admitted at our tertiary care centre between April and June 2020, whilst on lenalidomide-based therapy, two of whom underwent autologous stem cell transplant, with at least 30 days of follow-up.